Hematología y Hemoterapia

Resultados: 415
Tipo Título / Nombre Autor(es) Año
Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, et al 2018
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, et al 2018
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, et al 2018
Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia Ribera JM, García O, Gil C, Mercadal S, García-Cadenas I, Montesinos P, et al 2018
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, et al 2018
A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia García-Gutiérrez V, Gómez-Casares MT, Puerta JM, Alonso-Domínguez JM, Osorio S, Hernández-Boluda JC, et al 2017
Síndrome coronario agudo en pacientes con trombocitopenia. Respuesta Bermejo N 2017
Long Term Antiaggregation in a Patient with Severe Factor XI Deficiency Sigüenza R, Bermejo N, Casas I, Pérez Leal F, Cáceres S, Ibáñez F, et al 2017
Biological characterization of ITP patients that are non-responders to traditional therapies Rodríguez Otero P, Mateos MV, Joaquín ML, Miguel Teodoro H, Enrique MO, Rosiñol L, et al 2017
Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) Deveaux M, Stahl M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al 2017